Leaders in Supply & Demand Side Intelligence

Forgot your login?

Enter the e-mail address you used when you registered an account with IIR Energy.

A message will be sent to the E-Mail Address found in our records containing the associated username(s) as well as instructions for a password reset.


Sun Pharma Starts Phytopharmaceutical Dengue Drug Trial for COVID-19, an Industrial Info Market Brief

Free News Article
India Pharma
Attachment Included

Indian pharma-giant Sun Pharmaceutical Industries Limited announced that it has commenced Phase II clinical trials on AQCH, a phytopharmaceutical experimental drug for treatment of COVID-19. The company has already received approval from the Drugs Controller General of India (DCGI) for conducting the trial.

The drug, which is being developed for treatment of dengue fever, has shown anti-SARS-CoV-2 effects in in-vitro studies conducted in collaboration with International Center for Genetic Engineering and Biotechnology (ICGEB) in Italy and hence is being tested as a potential treatment option for COVID-19.

Details on this Article:
Industry Segment: Market Brief
Word Count: 155 Words
Attachment: India Pharma
Listen to Today's News News Audio Library Sync News Podcasts

Login or Register now for instant access!
Related Articles


This article is free for all Registered Members.

Register Now! All Fields are Required...

Pricing Help?

Upgrade your Premium News Subscription to include all archived articles for only $160. Contact Member Services: 800-762-3361

All Members Receive the Following Free Resources:

  • North American Project & Gap Spending
  • North American Plant Analysis by Industry & Market Region
  • Market Maps & Stats - Capital & Maintenance Activity
  • Current & Historic Economic Indicators
  • 30/60/90 Day Weather Forecast